ICELL RECEIVES SUPPORT FROM THE NATIONAL RESEARCH COUNCIL'S INDUSTRIAL RESEARCH ASSISTANCE PROGRAM

iCell Therapeutics is pleased to announce that it has received support from the National Research Council of Canada's -- Industrial Research Assistance Program (NRC-IRAP) for development of the company's LDE-TTX technology for treatment of Cancer. NRC-IRAP's contribution will support the scale up and pre-clinical development of iCell's LDE-TTX drug candidate. iCell has already completed several successful pre-clinical and clinical trials in Brazil which have demonstrated the safety of LDE-TTX.

Biotech Intelligence (http://www.biotech-intelligence.com/html/html/a9f3c0e8484aa74e3bb5d141ee63335e.html)